AB1081 A COMPARATIVE STUDY ON THE FEATURES OF THE SPINAL INVOLVEMENT IN SAPHO SYNDROME

Abstract

Background SAPHO syndrome is a rare disease with the typical involvement of the anterior chest wall. The spinal involvement is more often than we thought and less understood by us. Objectives To assess the clinical and imaging features of the spinal involvement in SAPHO syndrome. Methods Patients diagnosed with SAPHO syndrome in Peking University Third Hospital from 2006 to 2018 were recruited. Patients were divided into spinal involvement group and non-spinal involvement group. Patients with AS (ankylosing spondylitis) were recruited as control group. Their clinical data, laboratory data and imaging data (CT, MRI and radionuclide imaging) were collected and were conpared. All the patients with SAPHO syndrome were followed up regularly. Results Totally 46 SAPHO patients were included (17 male and 29 female) and 34 patients (73.9%) had spinal involvement. The mean age was 50.2±10.9 years and the mean disease duration was 5.4±6.4 years. 50 patients with AS were also included. Compared with non-spinal involvement group, the age at disease onset in spinal involvement group was older, the disease duration was longer,t;he CRP elevation was more often and the anterior chest wall involvement was less often (table 1). In spinal involvement group, the thoracic spine was most commonly involved and the vertebral inflammatory changes including bone marrow edema were often seen. These patients were more likely to suffer from cervical spine involvement, endplate inflammation and spondyldiscitis (table 2). All the SAPHO patients with spinal involvement were followed up. 30 patients received NSAIDs plus DMARDS/biologics and the symptoms improved. Reexamined imaging data of 10 patients were available and the spinal involvement became better. Conclusion 73.9% of SAPHO patients had spinal involvement and they were more likely to suffer from cervical spine involvement, endplate inflammation and spondyldiscitis. The combination of NSAIDS and biologics/DMARDs were helpful to improve the symptoms.